Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Retatrutide's primary mechanism of action involves modulating the activity of the endocannabinoid system, a complex network of receptors and signaling molecules that play a crucial role in maintaining homeostasis within the body
Medicaid) model, launched January 2026, is a related initiative aimed at reducing Medicaid drug costs
Retatrutide is an investigational GIP, GLP-1, and glucagon triple receptor agonist not yet approved by the MHRA or EMA
Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/beta-endorphin pathway
do NOT freeze after reconstitution Reconstitution Solvent: Bacteriostatic water (recommended)
Avoid repeated freezethaw cycles to maintain stability and ensure reproducible experimental results
US$ 20.39
US$ 23.93
US$ 29.23
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
US$ 20.42
US$ 21.34
